1. Home
  2. MREO vs BCHT Comparison

MREO vs BCHT Comparison

Compare MREO & BCHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.30

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$2.08

Market Cap

55.0M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
MREO
BCHT
Founded
2015
N/A
Country
United Kingdom
United States
Employees
N/A
15
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
52.5M
55.0M
IPO Year
2017
2026

Fundamental Metrics

Financial Performance
Metric
MREO
BCHT
Price
$0.30
$2.08
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$1.50
$15.00
AVG Volume (30 Days)
4.2M
126.4K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$500,000.00
N/A
Revenue This Year
$5,184.20
$13.42
Revenue Next Year
$55.51
$61.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.26
52 Week High
$2.94
$2.45

Technical Indicators

Market Signals
Indicator
MREO
BCHT
Relative Strength Index (RSI) 50.83 62.91
Support Level $0.22 $1.36
Resistance Level $0.36 $2.28
Average True Range (ATR) 0.04 0.23
MACD 0.00 0.05
Stochastic Oscillator 45.09 79.46

Price Performance

Historical Comparison
MREO
BCHT

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

Share on Social Networks: